Solid dispersions containing selepag, their preparation methods and applications

By preparing a solid dispersion of selepag and using a specific hydroxypropyl methylcellulose as a carrier, the problem of low solubility of selepag was solved, thereby improving its dissolution and bioavailability.

CN116785244BActive Publication Date: 2026-11-10SHANGHAI FOREFRONT PHARMCEUTICAL CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202310782428.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-29
Publication Date
2026-11-10
Estimated Expiration
2043-06-29

AI Technical Summary

Technical Problem

Selepag's crystal form I has low solubility in water, which affects the drug's bioavailability. Existing technologies make it difficult to improve its solubility while maintaining its efficacy.

Method used

A solid dispersion of selepag was prepared using hydroxypropyl methylcellulose with a specific ratio and viscosity as a carrier. By blocking the crystallization of selepag, its amorphous state was maintained, thereby increasing its dispersibility and stability.

Benefits of technology

It improves the dissolution and bioavailability of selepag while maintaining drug stability, simplifying formulation production and ensuring drug homogeneity in the formulation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116785244B_ABST
    Figure CN116785244B_ABST
Patent Text Reader

Abstract

This invention relates to a selepag-containing solid dispersion, its preparation method, and its applications. The selepag-containing solid dispersion comprises selepag and a carrier; the weight ratio of selepag to the carrier is <1:2.3; the carrier is hydroxypropyl methylcellulose; at 20°C, the viscosity of an aqueous solution containing 2% hydroxypropyl methylcellulose at a mass concentration is ≥2000 mPa·s. This solid dispersion exhibits good stability, good dispersibility, is not prone to crystallization, has high solubility, high bioavailability, and broad application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of pharmaceutical formulation technology, and in particular to a solid dispersion containing selepag, its preparation method, and its application. Background Technology

[0002] Selexipag, with the structural formula shown in Formula (I), and the chemical name 2-{4-[(5,6-diphenyl-2-pyrazinyl)(isopropyl)amino]butoxy}-N-(methanesulfonyl)acetamide, is an oral, highly selective, long-acting prodrug of prostacyclin (IP) receptor agonists. It can improve endothelial-dependent vasodilation of damaged pulmonary arteries and may inhibit the proliferation of human pulmonary smooth muscle cells and the thickening of pulmonary vessel walls.

[0003]

[0004] The original patent CN102459198A discloses three crystal forms of selepag: crystal form I, crystal form II, and crystal form III. Uptravi, a drug developed by Nippon Shinyaku Co., Ltd., uses crystal form I, which is a thermodynamically metastable crystal form with good stability, but has very low solubility in water, affecting the bioavailability of the drug.

[0005] It is evident that while selexipag has good efficacy, its shortcomings are also obvious. How to increase the solubility of selexipag while maintaining its efficacy is a problem that the industry urgently needs to solve. Summary of the Invention

[0006] Based on this, the purpose of the present invention is to provide a solid dispersion containing selepag that has good stability, good dispersibility and is not prone to crystallization, which can increase the solubility of selepag and improve its bioavailability.

[0007] The technical solution is as follows:

[0008] A solid dispersion containing sleptag, comprising sleptag and a carrier;

[0009] The weight ratio of the sleipag to the carrier is <1:2.3;

[0010] The carrier is hydroxypropyl methylcellulose (HPMC);

[0011] At 20°C, the viscosity of an aqueous solution containing the hydroxypropyl methylcellulose at a mass concentration of 2% is ≥2000 mPa·s.

[0012] In one embodiment, the weight ratio of the sleipag to the carrier is 1:(2.5 to 99).

[0013] In one embodiment, at 20°C, the viscosity of the aqueous solution containing the hydroxypropyl methylcellulose at a mass concentration of 2% is 2000 mPa·s to 10000 mPa·s.

[0014] In one embodiment, at 20°C, the viscosity of the aqueous solution containing the hydroxypropyl methylcellulose at a mass concentration of 2% is 2500 mPa·s to 6000 mPa·s.

[0015] In one embodiment, the weight-average molecular weight of the hydroxypropyl methylcellulose is ≥50,000.

[0016] In one embodiment, the hydroxypropyl methylcellulose is selected from at least one of HPMC K4M and HPMC E4M.

[0017] The present invention also provides a method for preparing a solid dispersion containing sleipag, comprising the following steps:

[0018] Sleipag and hydroxypropyl methylcellulose were mixed in a solvent to prepare a mixture;

[0019] Remove the solvent from the mixture;

[0020] Wherein, the weight ratio of the selepag to the hydroxypropyl methylcellulose is <1:2.3;

[0021] At 20°C, the viscosity of an aqueous solution containing the hydroxypropyl methylcellulose at a mass concentration of 2% is ≥2000 mPa·s.

[0022] In one embodiment, the solvent is selected from at least one of methanol, ethanol, propanol, isopropanol, and 2-methyl-2-propanol.

[0023] In one embodiment, the weight ratio of the sleipag to the solvent is 1:(200-10000).

[0024] In one embodiment, the weight ratio of the sleipag to the solvent is 1:(293-10000).

[0025] In one embodiment, the weight ratio of the sleipag to the solvent is 1:(300-6500).

[0026] In one embodiment, the weight ratio of the sleipag to the solvent is 1:(312-6250).

[0027] In one embodiment, the solvent is removed from the mixture by at least one of spray drying, evaporation, vacuum evaporation, and freeze drying.

[0028] This invention also provides another method for preparing a solid dispersion containing sleipag, comprising the following steps:

[0029] Sleipag and hydroxypropyl methylcellulose were mixed and then hot-melt extrusion was used to prepare a solid dispersion containing sleipag.

[0030] Wherein, the weight ratio of the selepag to the hydroxypropyl methylcellulose is <1:2.3;

[0031] At 20°C, the viscosity of an aqueous solution containing the hydroxypropyl methylcellulose at a mass concentration of 2% is ≥2000 mPa·s.

[0032] Optionally, the temperature of the hot melt extrusion is 80℃~250℃.

[0033] This invention also provides applications of solid dispersions containing sleipag. The technical solution is as follows:

[0034] A drug comprising a solid dispersion containing selepag as described above.

[0035] In one embodiment, the drug further comprises at least one pharmaceutically acceptable excipient.

[0036] In one embodiment, the dosage form of the drug is a tablet, granule, capsule, pill, film, or implant.

[0037] The present invention also provides the use of the drug as described above in the preparation of a pulmonary artery endothelium-dependent vasodilator that improves damage.

[0038] The present invention has at least the following beneficial effects:

[0039] Due to the ordered and periodic arrangement of molecules in crystalline substances, the energy of intermolecular interactions is reduced, resulting in lower energy, difficulty in dispersion, and low solubility. To reduce the crystallization of selexipag, this invention creatively prepares selexipag into a solid dispersion, thereby increasing its dispersibility and stability, and ultimately increasing its solubility.

[0040] Specifically, this invention provides a solid dispersion containing selexiparg, which uses hydroxypropyl methylcellulose (HMC) of a specific amount and viscosity as a solid dispersant (or drug carrier). The network structure of HMC blocks selexiparg molecules, inhibiting their crystallization and maintaining them stably in an amorphous state. Due to the highly disordered molecular state, selexiparg has a higher surface free energy than molecules in crystalline solids, making it easier to disperse, thereby increasing its solubility and bioavailability. Furthermore, this solid dispersion also exhibits excellent stability.

[0041] The method for preparing the solid dispersion of the present invention is simple to operate, uses inexpensive and readily available raw materials, is technically mature, has controllable costs, is easy to implement, and can be industrialized. Attached Figure Description

[0042] Figure 1 The present invention provides comparative examples of the solubility results of sleipag solid dispersions prepared using different carriers in different pH media.

[0043] Figure 2 The results show the dissolution rate of a solid dispersion containing selepag with a drug loading of 2.2% prepared in the comparative examples of this invention at pH 1.

[0044] Figure 3 The results show the dissolution rate of a solid dispersion containing selepag with a drug loading of 2.2% prepared in the comparative examples of this invention at pH 2.

[0045] Figure 4 The results show the dissolution rate of a solid dispersion containing selepag with a drug loading of 2.2% prepared in the comparative examples of this invention at pH 3.

[0046] Figure 5 The results show the dissolution rate of a solid dispersion containing selepag with a drug loading of 2.2% prepared in the comparative examples of this invention at pH 5.

[0047] Figure 6 The results show the dissolution rate of a solid dispersion containing selepag with a drug loading of 2.2% prepared in the comparative examples of this invention at pH 7.

[0048] Figure 7 The carrier prepared for this embodiment of the invention is HPMC E4M, and the dissolution rate of solid dispersions containing selepag with different drug loadings at pH 1 is shown.

[0049] Figure 8 The carrier prepared for this embodiment of the invention is HPMC E4M, and the dissolution rate of solid dispersions containing selepag with different drug loadings at pH 2 is shown.

[0050] Figure 9 The carrier prepared for this embodiment of the invention is HPMC E4M, and the dissolution rate of solid dispersions containing selepag with different drug loadings at pH 3 is shown.

[0051] Figure 10 The carrier prepared for this embodiment of the invention is HPMC E4M, and the dissolution rate of solid dispersions containing selepag with different drug loadings at pH 5 is shown.

[0052] Figure 11The carrier prepared for this embodiment of the invention is HPMC E4M, and the dissolution rate of solid dispersions containing selepag with different drug loadings at pH 7 is shown.

[0053] Figure 12 The dissolution rate of solid dispersions containing selepag with HPMC E4M or HPMC K4M as the carrier prepared for embodiments of the present invention at pH 1.

[0054] Figure 13 The dissolution rate of solid dispersions containing selepag with HPMC E4M or HPMC K4M as the carrier prepared for embodiments of the present invention at pH 2.

[0055] Figure 14 The dissolution rate of solid dispersions containing selepag with HPMC E4M or HPMC K4M as the carrier prepared for embodiments of the present invention at pH 3.

[0056] Figure 15 The dissolution rate of solid dispersions containing selepag with HPMC E4M or HPMC K4M as the carrier prepared for embodiments of the present invention at pH 5.

[0057] Figure 16 The dissolution rate of solid dispersions containing selepag with HPMC E4M or HPMC K4M as the carrier prepared for embodiments of the present invention at pH 7.

[0058] Figure 17 The XRD analysis results are for the blank excipient HPMC K4M;

[0059] Figure 18 XRD results for selepag solid dispersion with a drug loading of 1% under accelerated stability conditions at 0 days and 3 months;

[0060] Figure 19 XRD results for selepag solid dispersion with a drug loading of 10% under accelerated stability conditions at 0 days and 3 months;

[0061] Figure 20 XRD results for selepag solid dispersion with a drug loading of 15% under accelerated stability conditions at 0 days and 3 months;

[0062] Figure 21 XRD results for selepag solid dispersion with a drug loading of 20% under accelerated stability conditions at 0 days and 3 months;

[0063] Figure 22 XRD results for selepag solid dispersion with 20% drug loading and double the solvent under accelerated stability conditions at 0 days, 1 month and 3 months;

[0064] Figure 23 XRD results for selepag solid dispersion with a drug loading of 30% under accelerated stability conditions at 0 days, 1 month, and 3 months;

[0065] Figure 24 XRD results for selepag solid dispersion with 50% drug loading under accelerated stability conditions at 0 days, 1 month, and 3 months. Detailed Implementation

[0066] The present invention will be further described in detail below with reference to specific embodiments. The present invention can be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to provide a thorough and complete understanding of the disclosure of the present invention.

[0067] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The terminology used herein in the specification of this invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. The term "and / or" as used herein includes any and all combinations of one or more of the associated listed items.

[0068] When using “including,” “having,” and “contains” as described herein, the intention is to cover non-exclusive inclusion, unless an explicit qualifying term such as “only,” “consisting of,” etc., is used, in which case another component may be added.

[0069] In this invention, the terms "preferredly," "more preferably," "better," and "even better" refer to embodiments of the invention that provide certain beneficial effects under certain circumstances. However, other embodiments may also be preferred under the same or other circumstances. Furthermore, the description of one or more preferred embodiments does not imply that other embodiments are unavailable, nor is it intended to exclude other embodiments from the scope of the invention. That is, in this invention, "preferredly," "more preferably," "better," and "even better" are merely descriptions of more effective implementations or examples, but do not constitute a limitation on the scope of protection of the invention.

[0070] In this invention, terms such as "further," "even more," and "particularly" are used for descriptive purposes and to indicate differences in content, but should not be construed as limiting the scope of protection of this invention.

[0071] In this invention, "at least one" means one or more, such as one, two, or more. "Multiple" or "several" means at least two, such as two, three, etc., and "multi-layered" means at least two layers, such as two layers, three layers, etc., unless otherwise explicitly specified. In the description of this invention, "several" means at least one, such as one, two, etc., unless otherwise explicitly specified.

[0072] When a numerical range is disclosed herein, the range is considered continuous and includes the minimum and maximum values ​​of the range, as well as every value between the minimum and maximum values. Furthermore, when the range refers to integers, it includes every integer between the minimum and maximum values ​​of the range. Additionally, when multiple ranges are provided to describe a feature or characteristic, the ranges may be combined. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges to which they are incorporated.

[0073] Unless otherwise specified, all steps of this invention may be performed sequentially or randomly. For example, the method includes steps (a) and (b), indicating that the method may include steps (a) and (b) performed sequentially, or it may include steps (b) and (a) performed sequentially. For example, the method may also include step (c), indicating that step (c) may be added to the method in any order. For example, the method may include steps (a), (b), and (c), or it may include steps (a), (c), and (b), or it may include steps (c), (a), and (b), etc.

[0074] Unless otherwise stated, a singular term may include a plural term and should not be understood as having a quantity of one.

[0075] Uptravi, a drug developed by Nippon Shinyaku Co., Ltd., uses selepag in crystal form I, which is a thermodynamically metastable crystal form with good stability. However, it has very low solubility in water, affecting the bioavailability of the drug. How to increase the solubility of selepag while maintaining its efficacy is an urgent problem to be solved in the industry.

[0076] Given that the solid form of a drug directly affects the dissolution rate of the active pharmaceutical ingredient, the dissolution rate of the formulation, and its bioavailability, and considering that drugs can exist in both crystalline and amorphous states, the amorphous state, as a special form of solid matter, has important applications in drug preparation, the inventors creatively formulated selexipag into a solid dispersion to address its tendency to crystallize and its poor dissolution. This increased dispersibility and stability, thereby enhancing its dissolution rate. The specific details are as follows:

[0077] This invention provides a solid dispersion containing selepag that has good stability, good dispersibility, and is not prone to crystallization, which can increase the solubility of selepag and improve its bioavailability.

[0078] The technical solution is as follows:

[0079] A solid dispersion containing sleptag, comprising sleptag and a carrier;

[0080] The weight ratio of the sleipag to the carrier is <1:2.3;

[0081] The carrier is hydroxypropyl methylcellulose;

[0082] At 20°C, the viscosity of an aqueous solution containing the hydroxypropyl methylcellulose at a mass concentration of 2% is ≥2000 mPa·s.

[0083] This invention uses hydroxypropyl methylcellulose (HMC) of a specific dosage and viscosity as a solid dispersant (or drug carrier). The network structure of HMC blocks selexipag molecules, inhibiting crystallization and maintaining their stable amorphous state. Due to the highly disordered molecular state, selexipag has a higher surface free energy than molecules in crystalline solids, making it easier to disperse, thereby increasing its solubility and bioavailability. Furthermore, this solid dispersion exhibits excellent stability.

[0084] Furthermore, since the original drug Uptravi tablets have a minimum strength of 0.2 mg and a maximum strength of 1.6 mg, the amount of active pharmaceutical ingredient (API) added in the formulation is low, making it challenging to ensure the uniformity of selexipag content in the tablets. This invention prepares selexipag into a solid dispersion, which facilitates subsequent formulation production and ensures the uniformity of selexipag content in the formulation.

[0085] The inventors discovered that the drug loading ratio has a significant impact on the dispersibility of solid dispersions. If the drug loading ratio is lower than that of this invention, the hydroxypropyl methylcellulose content will be too low, making it difficult to effectively block and inhibit the crystallization of selepag molecules.

[0086] In this invention, the weight ratio of the selepag to the carrier is <1:2.3. It is understood that the weight ratio of the selepag to the carrier includes, but is not limited to, 1:2.4, 1:2.5, 1:2.6, 1:2.8, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.67, 1:6, 1:7, 1:8, 1:9, 1:10, and 1:6. 1:7, 1:8, 1:9, 1:10, 1:12, 1:15, 1:18, 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, 1:50, 1:55, 1:60, 1:65, 1:70, 1:75, 1:80, 1:85, 1:90, 1:95, 1:99, 1:100, 1:105, or 1:110.

[0087] In one embodiment, the weight ratio of the sleipag to the carrier is 1:(2.5 to 99).

[0088] In one embodiment, the weight ratio of the sleipag to the carrier is 1:(4-99).

[0089] In one embodiment, the weight ratio of the sleipag to the carrier is 1:4, 1:5.67, 1:9, or 1:99.

[0090] The inventors discovered that the viscosity of hydroxypropyl methylcellulose has a significant impact on the dispersibility of solid dispersions. If the viscosity of hydroxypropyl methylcellulose is too low, it is outside the scope of this invention and will be difficult to effectively block Sleipag molecules and inhibit their crystallization.

[0091] In this invention, at 20°C, the viscosity of the aqueous solution containing the hydroxypropyl methylcellulose at a mass concentration of 2% is ≥2000 mPa·s, including but not limited to 2000 mPa·s, 3000 mPa·s, 4000 mPa·s, 5000 mPa·s, 6000 mPa·s, 7000 mPa·s, 8000 mPa·s, 9000 mPa·s, 10000 mPa·s, or 12000 mPa·s.

[0092] In one embodiment, at 20°C, the viscosity of the aqueous solution containing the hydroxypropyl methylcellulose at a mass concentration of 2% is 2000 mPa·s to 10000 mPa·s.

[0093] In one embodiment, at 20°C, the viscosity of the aqueous solution containing the hydroxypropyl methylcellulose at a mass concentration of 2% is 2500 mPa·s to 6000 mPa·s.

[0094] In one embodiment, at 20°C, the viscosity of the aqueous solution containing the hydroxypropyl methylcellulose at a mass concentration of 2% is 2700 mPa·s to 5500 mPa·s.

[0095] It should be noted that hydroxypropyl methylcellulose (HPMC) is a polymer and a mixture. The product manual usually lists a specific value, while the actual viscosity is a range. For example: 1) HPMC E4M, the product manual shows a viscosity of 4000 mPa·s. At 20°C, the actual viscosity of an aqueous solution containing 2% HPMC E4M is 2700 mPa·s to 5040 mPa·s. 2) For example, HPMC E10M, the product manual shows a viscosity of 10000 mPa·s. At 20°C, the actual viscosity of an aqueous solution containing 2% HPMC E10M is 7500 mPa·s to 14000 mPa·s. 3) HPMC E50, the product manual shows a viscosity of 50 mPa·s. At 20°C, the actual viscosity of an aqueous solution containing 2% HPMC E50 is 40 mPa·s to 60 mPa·s. In this invention, it is required that the maximum actual viscosity of an aqueous solution containing 2% hydroxypropyl methylcellulose at 20°C is ≥2000 mPa·s. Preferably, the minimum actual viscosity of the aqueous solution containing 2% hydroxypropyl methylcellulose at 20°C is ≥2000 mPa·s.

[0096] In one embodiment, the weight-average molecular weight of the hydroxypropyl methylcellulose is ≥50,000, including but not limited to 50,000, 100,000, 150,000, 200,000, 250,000, 300,000, 350,000, 400,000, 500,000, 550,000, 600,000 or 1,000,000.

[0097] In one embodiment, the weight-average molecular weight of the hydroxypropyl methylcellulose is 100,000 to 500,000.

[0098] In one embodiment, the hydroxypropyl methylcellulose is selected from at least one of HPMC K4M and HPMC E4M, that is, the hydroxypropyl methylcellulose is selected from HPMC K4M, or HPMC E4M, or a mixture of HPMC K4M and HPMC E4M.

[0099] The present invention also provides a method for preparing a solid dispersion containing sleipag, comprising the following steps:

[0100] Sleipag and hydroxypropyl methylcellulose were mixed in a solvent to prepare a mixture;

[0101] Remove the solvent from the mixture;

[0102] Wherein, the weight ratio of the selepag to the hydroxypropyl methylcellulose is <1:2.3;

[0103] At 20°C, the viscosity of an aqueous solution containing the hydroxypropyl methylcellulose at a mass concentration of 2% is ≥2000 mPa·s.

[0104] The preparation method of the above-mentioned solid dispersion of the present invention is simple to operate, the raw materials are inexpensive and easy to obtain, the technology is mature, the cost is controllable, it is easy to implement, and it can be industrialized.

[0105] Understandably, the requirements for the weight ratio of selexiparg and the hydroxypropyl methylcellulose, as well as the viscosity of the hydroxypropyl methylcellulose, in the preparation method of the solid dispersion of the present invention are consistent with those in the solid dispersion above, and will not be repeated here.

[0106] In one embodiment, the solvent is selected from at least one of methanol, ethanol, propanol, isopropanol, and 2-methyl-2-propanol.

[0107] In one embodiment, the weight ratio of the selepag to the solvent is 1:(200-10000), including but not limited to 1:200, 1:220, 1:250, 1:280, 1:293, 1:300, 1:312, 1:350, 1:400, 1:450, 1:500, 1:550, 1:600, 1:650, 1:700, 1:750, 1:800, 1:850, 1:900, 1:950, 1:1000, 1:1050, 1:1100, 1:1200, 1:1300, 1:1500, 1:1800, 1:2000, 1:2200, etc. 1:2500, 1:2800, 1:3000, 1:1200, 1:2200, 1:2500, 1:2800, 1:3000, 1:3200, 1:3500, 1:3800, 1:4000, 1:4200, 1:4500, 1:4800, 1:5000, 1:5200, 1:5500, 1:5800, 1:6000, 1:6100, 1:6200, 1:6250, 1:6300, 1:6400, 1:6500, 1:7000, 1:7500, 1:8000, 1:8500, 1:9000, 1:9500, or 1:10000. Preferably, the weight ratio of selexipag to the solvent is 1:(300-6500). Preferably, the weight ratio of selexipag to the solvent is 1:(312-6250).

[0108] In one embodiment, the solvent is removed from the mixture by at least one of spray drying, evaporation, vacuum evaporation, and freeze drying. Preferably, the solvent is removed by spray drying, which converts the crystalline raw material into an amorphous state, thereby increasing the solubility and bioavailability of the drug.

[0109] In one embodiment, the solvent in the mixture is removed by spray drying. Further, the spray drying temperature is 85°C to 160°C, including but not limited to 85°C, 90°C, 95°C, 100°C, 110°C, 120°C, 130°C, 140°C, 150°C, or 160°C.

[0110] This invention also provides another method for preparing a solid dispersion containing sleipag, comprising the following steps:

[0111] Sleipag and hydroxypropyl methylcellulose were mixed and then hot-melt extrusion was used to prepare a solid dispersion containing sleipag.

[0112] Wherein, the weight ratio of the selepag to the hydroxypropyl methylcellulose is <1:2.3;

[0113] At 20°C, the viscosity of an aqueous solution containing the hydroxypropyl methylcellulose at a mass concentration of 2% is ≥2000 mPa·s.

[0114] The method for preparing the solid dispersion described above in this invention uses hot melt extrusion to convert crystalline raw materials into an amorphous state, which can increase the solubility and bioavailability of the drug. In addition, this method also has the advantages of simple operation, inexpensive and readily available raw materials, mature technology, controllable cost, easy implementation, and industrial production capability.

[0115] Optionally, the hot melt extrusion temperature is 80℃ to 250℃, including but not limited to 80℃, 90℃, 100℃, 110℃, 120℃, 130℃, 140℃, 150℃, 160℃, 170℃, 180℃, 190℃, 200℃, 210℃, 220℃, 230℃, 240℃, or 250℃. Preferably, the hot melt extrusion temperature is 100℃ to 200℃. More preferably, the hot melt extrusion temperature is 110℃ to 180℃.

[0116] This invention also provides applications of solid dispersions containing sleipag. The technical solution is as follows:

[0117] A drug comprising a solid dispersion containing selepag as described above.

[0118] In one embodiment, the drug further comprises at least one pharmaceutically acceptable excipient.

[0119] In one embodiment, the excipient is selected from at least one of HPMC E3, HPMC E5, HPC LF, PVP K30, HPMCE50, HPMC E4M and HPMC K4M.

[0120] In one embodiment, the dosage form of the drug is a tablet, granule, capsule, pill, film, or implant.

[0121] In one embodiment, the dosage form of the drug is a tablet.

[0122] The present invention also provides the use of the drug as described above in the preparation of a pulmonary artery endothelium-dependent vasodilator that improves damage.

[0123] The present invention will be further described below with reference to specific embodiments.

[0124] Examples 1 to 11

[0125] Examples 1 to 11 provide solid dispersions containing sleipag and methods for their preparation, as detailed below:

[0126] Referring to the parameters in Table 1, selepag and hydroxypropyl methylcellulose HPMC K4M or HPMC E4M were used to prepare a solid dispersion containing selepag.

[0127] Table 1

[0128]

[0129] Comparative Example 1

[0130] Comparative Example 1 provides a solid dispersion containing selepag and its preparation method, as follows: referring to the parameters in Table 2, selepag and HPMC E3 are prepared into a solid dispersion containing selepag.

[0131] Table 2

[0132]

[0133] Comparative Example 2

[0134] Comparative Example 2 provides a solid dispersion containing selepag and its preparation method, as follows: referring to the parameters in Table 3, selepag and HPMC E5 are prepared into a solid dispersion containing selepag.

[0135] Table 3

[0136]

[0137] Comparative Examples 3 to 6

[0138] Comparative Examples 3 to 6 provide solid dispersions containing selepag and their preparation methods, as follows: referring to the parameters in Table 4, selepag and HPMC E50 are prepared into solid dispersions containing selepag.

[0139] Table 4

[0140]

[0141] Comparative Example 7

[0142] Comparative Example 7 provides a solid dispersion containing selepag and its preparation method, as detailed below:

[0143] Referring to the parameters in Table 5, sleipag and HPC LF were prepared into a solid dispersion containing sleipag.

[0144] Table 5

[0145]

[0146] Comparative Example 8

[0147] Comparative Example 8 provides a solid dispersion containing selepag and its preparation method, as detailed below:

[0148] Referring to the parameters in Table 6, sleipag and PVP K30 were prepared into a solid dispersion containing sleipag.

[0149] Table 6

[0150]

[0151] Comparative examples 9 to 10

[0152] Comparative Examples 9 and 10 provide solid dispersions containing selepag and methods for their preparation, as detailed below:

[0153] Referring to the parameters in Table 7, slepagan and hydroxypropyl methylcellulose HPMC K4M were used to prepare a solid dispersion containing slepagan.

[0154] Table 7

[0155]

[0156] test:

[0157] 1. The solubility of the solid dispersions containing selexipag (hereinafter abbreviated as SLXP SD) prepared in Examples 1 to 11 and Comparative Examples 1 to 10 were tested:

[0158] (1) Preparation of buffer solution:

[0159] Take 9.00 mL of hydrochloric acid, dilute with water to 1000 mL, and shake well to obtain a pH 1 buffer solution;

[0160] A pH2 buffer solution is obtained by diluting a pH2 buffer solution 10 times.

[0161] Buffer solutions with pH 3, pH 5, pH 7 and pH 9 were prepared using 50 mmol dipotassium hydrogen phosphate solution and potassium dihydrogen phosphate solution.

[0162] (2) Dissolution rate / solubility test:

[0163] Weigh 30 mg of SLXP SD with a drug loading of 2.2% into 10 mL of pH 1, pH 2, pH 3, pH 5, pH 7 and pH 9 buffer solutions respectively; place in a 37°C water bath and shake; collect the solution at different time points or after 24 hours, filter and determine the dissolution rate or solubility by HPLC.

[0164] 1.1 The solubility of SLXP SD with a drug loading of 2.2% prepared in each example and comparative example was tested under various pH conditions for 24 h.

[0165] 1.1.2 The solubility results of each SLXP SD and API with a drug loading of 2.2% under various pH conditions for 24 hours are shown in Table 8 below. Figure 1 .

[0166] Table 8. Solubility of each SLXP SD and API with a drug loading of 2.2% at various pH conditions for 24 h, in μg / mL.

[0167]

[0168] From Table 8 and Figure 1 It is known that all polymer carriers have a solubilizing effect on selepag, and HPMC E4M and K4M have significant solubilizing effects and are stable within 24 hours.

[0169] 1.2 Dissolution rate of each SLXP SD with a drug loading of 2.2% under various pH conditions.

[0170] The dissolution rates of each SLXP SD under different pH conditions are compared, and the results are shown in Tables 9 to 13 below. Figures 2 to 6 Among them, Table 9 and Figure 2 For the results at pH 1, see Table 10 and Figure 3 For the results at pH 2, see Table 11 and Figure 4 For the results at pH 3, see Table 12 and Figure 5 For results at pH 5, see Table 13 and Figure 6 The result is for a pH of 7.

[0171] Table 9 shows that pH is 1.

[0172]

[0173] Table 10 shows that pH is 2.

[0174]

[0175] Table 11 shows that pH is 3.

[0176]

[0177] Table 12 shows a pH of 5.

[0178]

[0179]

[0180] Table 13 shows a pH of 7.

[0181]

[0182] From Tables 9 to 13, and Figures 2 to 6 It can be seen that HPMC E4M and K4M have significant and stable solubilizing effects at various pH levels over 24 hours.

[0183] 1.3 The dissolution rate of SLXP SD with HPMC E4M as the test carrier and different drug loadings (2.2%, 5%, 10%, and 20%) under various pH conditions.

[0184] The dissolution rates of SLXP SDs with different drug loadings under different pH conditions were compared, and the results are shown in Tables 14 to 18 below. Figures 7 to 11 Among them, Table 14 and Figure 7 For results at pH 1, see Table 15 and Figure 8 For the results at pH 2, see Table 16 and Figure 9 For results at pH 3, see Table 17 and Figure 10 For results at pH 5, see Table 18 and Figure 11 The result is for a pH of 7.

[0185] Table 14 shows that pH is 1.

[0186]

[0187] Table 15 shows that pH is 2.

[0188]

[0189] Table 16 shows that pH is 3.

[0190]

[0191]

[0192] Table 17 shows that pH is 5.

[0193]

[0194] Table 18 shows a pH of 7.

[0195]

[0196]

[0197] From Tables 14 to 18, and Figures 7 to 11 It can be seen that when SLXP SDs with different drug loadings are prepared using HPMC E4M as a carrier, the solubility of SLXP increases proportionally to its drug loading.

[0198] 1.4 Comparison of the solubility rate of SLXP SD with HPMC K4M and HPMC E4M as carriers and a drug loading of 5% under various pH conditions.

[0199] 1.4.1 The dissolution rates of SLXP SD with HPMC K4M and HPMC E4M carriers and a drug loading of 5% were compared under various pH conditions. The results are shown in Table 19 below. Figures 12 to 16 .

[0200] Table 19

[0201]

[0202] From Table 19 and Figures 12 to 16 It can be seen that HPMC E4M and HPMC K4M have obvious and stable solubilizing effects at various pH values ​​over 24 hours. Moreover, the solid dispersion containing sleipag prepared using HPMC K4M as a carrier has better solubility than HPMC E4M.

[0203] 2. Stability study of SLXP SD: The chemical and physical stability of SLXP SD with different drug loadings (1%, 10%, 15%, 20%, 30% and 50%) was investigated in accelerated experiments (40℃, 75RH%).

[0204] 2.1 The ingredient list is shown in Table 20:

[0205] Table 20

[0206]

[0207] 2.2 Chemical stability

[0208] Test method: The sample was packaged in a PE bag + aluminum foil bag + desiccant, and stored at 40℃ and 75% RH. The test results are shown in Table 21 below.

[0209] Table 21

[0210]

[0211]

[0212] As shown in Table 21, based on purity and related material data, the selepag solid dispersion with a drug loading of 20% exhibits the best stability.

[0213] 2.3 Physical stability

[0214] Test method: Samples were packaged in PE bags + aluminum foil bags + desiccants, and stored at 40℃ and 75% RH; test results are shown below. Figures 18 to 24 The results are summarized in Table 22 below.

[0215] Figure 17 The results are XRD analysis results for the blank excipient HPMC K4M. Figure 18 XRD results for selexipag solid dispersion with a drug loading of 1% under accelerated stability conditions at 0 days and 3 months. Figure 19 XRD results for selexipag solid dispersion with a drug loading of 10% under accelerated stability conditions at 0 days and 3 months. Figure 20 XRD results for selexipag solid dispersion with a drug loading of 15% under accelerated stability conditions at 0 days and 3 months. Figure 21 XRD results for selexipag solid dispersion with a drug loading of 20% under accelerated stability conditions at 0 days and 3 months. Figure 22 The XRD results for selepag solid dispersion with 20% drug loading and double the solvent are presented under accelerated stability conditions at 0 days, 1 month, and 3 months. Figures 18 to 22 It can be seen that selepag solid dispersions with a drug dosage of 20% or more showed no crystal precipitation under accelerated stabilization conditions for 3 months, indicating good physical stability.

[0216] Figure 23 XRD results for selepag solid dispersion with a drug loading of 30% under accelerated stability conditions at 0 days, 1 month, and 3 months. Figure 24 The XRD results for selepag solid dispersion with a drug loading of 50% under accelerated stability conditions at 0 days, 1 month, and 3 months are presented by [data missing]. Figure 23 and Figure 24 It can be seen that solid dispersions of selepag with drug loading of 30% and 50% exhibit crystal precipitation under accelerated stabilization conditions for 3 months, indicating poor physical stability.

[0217] Table 22

[0218]

[0219]

[0220] As shown in Table 22, except for the selepag solid dispersions with drug loading of 30% and 50% which showed crystal precipitation under accelerated stabilization conditions for 3 months, the selepag solid dispersions with other drug loadings showed good physical stability and no crystal precipitation.

[0221] In summary, the selepag-containing solid dispersion provided by this invention can effectively inhibit selepag crystallization, keeping it stably in an amorphous state, making it easier to disperse, thereby increasing its solubility and improving its bioavailability. Furthermore, this solid dispersion also exhibits excellent stability.

[0222] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0223] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the protection scope of the present invention. Therefore, the protection scope of this invention patent should be determined by the appended claims.

Claims

1. A solid dispersion containing sleipag, characterized in that, The solid dispersion is composed of selexipag and a carrier; the weight ratio of selexipag to the carrier is 1:(4-5.67); the carrier is hydroxypropyl methylcellulose; The hydroxypropyl methylcellulose is selected from at least one of HPMC K4M and HPMC E4M; The solid dispersion is prepared by a method comprising the following steps: mixing selepag and hydroxypropyl methylcellulose in a solvent to prepare a mixture; removing the solvent from the mixture to prepare the solid dispersion containing selepag; wherein the solvent is a mixture of purified water and methanol in a volume ratio of 1:4, and the weight ratio of selepag to the solvent is 1:(200-600). Alternatively, selepag and hydroxypropyl methylcellulose can be mixed and the selepag-containing solid dispersion can be prepared by hot melt extrusion.

2. The solid dispersion containing Sleipag according to claim 1, characterized in that, The weight ratio of the sleipag to the carrier is 1:

4.

3. The solid dispersion containing Sleipäger according to claim 1, characterized in that, The hydroxypropyl methylcellulose is HPMCK4M.

4. A method for preparing a solid dispersion containing sleipag as described in claim 1, characterized in that, The process includes the following steps: mixing selepag and hydroxypropyl methylcellulose in a solvent to prepare a mixture; removing the solvent from the mixture to prepare the solid dispersion containing selepag; wherein the solvent is a mixture of purified water and methanol in a volume ratio of 1:4, and the weight ratio of selepag to the solvent is 1:(200-600). Alternatively, selepag and hydroxypropyl methylcellulose can be mixed and the selepag-containing solid dispersion can be prepared by hot melt extrusion.

5. The method for preparing a solid dispersion containing sleipag according to claim 4, characterized in that, The weight ratio of the sleipag and the hydroxypropyl methylcellulose is 1:

4.

6. The method for preparing a solid dispersion containing sleipag according to claim 4, characterized in that, The hydroxypropyl methylcellulose is HPMC K4M.

7. The use of the solid dispersion according to any one of claims 1 to 3 in the preparation of a pulmonary artery endothelium-dependent vasodilator to improve damage.

8. The application as described in claim 7, characterized in that, The drug comprises a solid dispersion containing selepag as described in any one of claims 1 to 3, and at least one pharmaceutically acceptable excipient.

9. The application according to claim 7, characterized in that, The dosage form of the drug is tablets, granules, capsules, pills, films, or implants.

Citation Information

Patent Citations

  • Crystals

    CN102459198A

  • Solid dispersoid of selexipag and pharmaceutic adjuvant and preparation method of solid dispersoid

    CN107286104A

  • Solid dispersion composition

    US20110052688A1